Skip to main content
. 2020 Mar;26(3):541–548. doi: 10.3201/eid2603.191018

Figure 1.

Figure 1

Enrollment and vaccination period for 84 participants in Sierra Leone Trial to Introduce a Vaccine against Ebola (STRIVE). Three participants randomized to the immediate group were unvaccinated. After vaccination, participants in the deferred group were eligible for vaccination at 18–24 weeks postenrollment. Upon vaccination, participants in the deferred group were referred to as the deferred crossover vaccinated group.